- Round ID
- FR-00054
- Stage
- Series B
- Round name
- Series B
- Amount
- $170M
Dated funding evidence
Beacon Therapeutics
Series B · $170M · 2024-07-01
Reported round$170MSeries B
- Disclosure date
- 2024-07-01
- Reported currency
- USD
- Companies House
- 14426488
- Evidence sources
- 2
2024-07-01Series B$170M
Resolved investor records
ForbionLead investorSynconaInvestorOxford Science EnterprisesInvestorUniversity of OxfordInvestorTCGXInvestorAdvent Life SciencesInvestor
Investor links inherit this round’s named source and date. Resolved links use an exact canonical investor name; unresolved names remain unlinked.
Record fields
What the source states
Amounts, currency, stage and investor names are preserved as reported. No FX conversion, valuation inference or current-holding claim is added.
- Lead investors
- Forbion
- Other investors
- Syncona, Oxford Science Enterprises, University of Oxford, TCGX, Advent Life Sciences
- Source layers
- VC research snapshot, Live Chris T D1
- Snapshot
- 2026-08-15
Named evidence
Source trail
This page is published only when the record has a resolved company, disclosure date, round stage and at least one retained source URL.